Sun Pharma Advanced Research Company Ltd

Sun Pharma Advanced Research Company Ltd (SPARC) is currently navigating a complex technical landscape as its price momentum shifts from mildly bearish to sideways. Despite a modest decline in daily price, key technical indicators such as MACD and KST suggest mild bullishness on weekly and monthly charts, while moving averages and Bollinger Bands present a more cautious outlook. This nuanced technical picture warrants close attention from investors amid the stock’s underperformance relative to the broader market.

Sun Pharma Advanced Research Company Ltd (SPARC) has experienced a subtle but notable shift in its technical momentum, moving from a mildly bullish stance to a mildly bearish outlook. This transition is underscored by mixed signals from key technical indicators such as MACD, RSI, Bollinger Bands, and moving averages, reflecting a complex market sentiment for this small-cap pharmaceutical and biotechnology stock.

Sun Pharma Advanced Research Company Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 01 Feb 2024, reflecting a shift from a previous 'Sell' grade. However, the analysis and financial metrics discussed below are based on the company's current position as of 20 April 2026, providing investors with an up-to-date view of the stock's fundamentals, valuation, financial trend, and technical outlook.

Sun Pharma Advanced Research Company Ltd (SPARC) has exhibited a notable shift in its technical momentum, moving from a sideways trend to a mildly bullish stance. Despite a strong day change of 5.76%, the stock’s technical indicators present a nuanced picture, reflecting both optimism and caution for investors navigating the Pharmaceuticals & Biotechnology sector.

The Sensex advanced 1.6% on 15 Apr 2026, yet Sun Pharma Advanced Research Company Ltd outpaced the broader market with a 7.06% gain, reaching an intraday high of Rs 148.75. This 3.25 percentage-point outperformance over its Pharmaceuticals & Biotechnology sector peers signals a distinctly stock-specific rally rather than a market-wide lift.

Sun Pharma Advanced Research Company Ltd (SPARC) has experienced a notable shift in its technical momentum, moving from a mildly bearish stance to a sideways trend. Despite a modest day gain of 1.47%, the stock’s technical indicators present a complex picture, with some signals suggesting mild bullishness while others remain neutral or bearish. This nuanced technical landscape warrants close attention from investors navigating the Pharmaceuticals & Biotechnology sector.

Sun Pharma Advanced Research Company Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 01 Feb 2024. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 09 April 2026, providing investors with an up-to-date view of its fundamentals, returns, and overall outlook.

The Sensex declined by 0.73% on 09 Apr 2026, while Sun Pharma Advanced Research Company Ltd surged 7.12%, outperforming its Pharmaceuticals & Biotechnology sector by over 8 percentage points. This sharp intraday gain stands out as a stock-specific event amid a broadly weak market environment.

The Sensex climbed 3.91% on 8 Apr 2026, yet Sun Pharma Advanced Research Company Ltd outpaced the broader market with an 8.2% gain, touching an intraday high of Rs 138.3. This 8.24 percentage-point outperformance over its Pharmaceuticals & Biotechnology sector peers signals a distinctly stock-specific rally rather than a mere market tailwind.

Sun Pharma Advanced Research Company Ltd (SPARC) commenced trading on 8 April 2026 with a notable gap up, opening 6.26% higher than its previous close. This strong start reflects positive market sentiment despite the company’s current 'Strong Sell' rating by MarketsMOJO, highlighting a complex interplay between short-term price action and longer-term technical assessments.

Sun Pharma Advanced Research Company Ltd (SPARC) has experienced a nuanced shift in its technical momentum, reflecting a complex interplay of bearish and mildly bullish indicators. Despite a recent uptick in price, the stock remains under pressure with a strong sell rating and a technical trend that has only marginally improved from bearish to mildly bearish, signalling cautious investor sentiment in the Pharmaceuticals & Biotechnology sector.

Sun Pharma Advanced Research Company Ltd (SPARC) commenced trading on 1 April 2026 with a significant gap up, opening 6.98% higher than its previous close. This strong start comes amid a backdrop of mixed technical signals and a recent upgrade in market sentiment, as reflected in its latest Mojo Grade.

Sun Pharma Advanced Research Company Ltd (SPARC) has experienced a notable shift in its technical momentum, with key indicators signalling a bearish trend. The stock’s recent price action, combined with deteriorating technical parameters, underscores mounting challenges for investors in this small-cap pharmaceutical and biotechnology firm.

Sun Pharma Advanced Research Company Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 01 Feb 2024. However, the analysis and financial metrics discussed here reflect the stock's current position as of 29 March 2026, providing investors with an up-to-date view of the company’s performance and outlook.

Sun Pharma Advanced Research Company Ltd experienced a significant intraday decline on 27 Mar 2026, touching a low of Rs 121.55, down 7.74% from the previous close. The stock underperformed its sector and the broader market, reflecting immediate selling pressure amid a broadly negative market environment.